INNOVIVA,INC. (NASDAQ:INVA) Files An 8-K Other Events
Item 8.01. Other Events.
On April10, 2017,Innoviva,Inc. announced that it planned to
prepay $50 million in outstanding principal on its non-recourse
royalty notes due 2029 as part of its previously announced $150
million capital return program for 2017. The press release is
filed as Exhibit99.1 to this report and is incorporated herein by
reference.
Item9.01. Financial Statements and Exhibits.
(d)Exhibits
99.1 |
Press Release dated April10, 2017 |
About INNOVIVA, INC. (NASDAQ:INVA)
Innoviva, Inc., formerly Theravance, Inc., is engaged in the development, commercialization and financial management of bio-pharmaceuticals. It focuses on the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate (FF)/vilanterol (VI)) and ANORO ELLIPTA (umeclidinium bromide/vilanterol (UMEC/VI)). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement and the Strategic Alliance Agreement with GSK, the Company is eligible to receive the annual royalties from GSK on sales of RELVAR/BREO ELLIPTA. For other products combined with a LABA from the LABA collaboration, such as ANORO ELLIPTA, royalties are upward tiering and range from 6.5% to 10%. RELVAR/BREO is a once-a-day combination inhaled respiratory medicine consisting of a LABA (VI) and an inhaled corticosteroid (ICS), FF. ANORO ELLIPTA a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA. INNOVIVA, INC. (NASDAQ:INVA) Recent Trading Information
INNOVIVA, INC. (NASDAQ:INVA) closed its last trading session up +0.60 at 14.22 with 9,868,603 shares trading hands.